Program
zagociguat
Also written as “zagociguat 15mg”, “CY6463” and “IW-6463”.
Its studies are mostly in Acidosis, Lactic · Alzheimer Disease · MELAS Syndrome · Schizophrenia, led by Tisento Therapeutics.
Furthest: phase 2, since Jul 14, 20207 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tisento Therapeutics | 70 open or running | phase 2since Jul 14, 2020 | Feb 20, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 20, 2019First study: phase 1 study in OtherFirst studyNCT03856827 · 110 enrolled · Netherlands
- Jan 21, 2020Phase 1 study in OtherNCT04240158 · 24 enrolled · Netherlands
- Jul 14, 2020Phase 2 study in MELAS SyndromeNCT04475549 · 8 enrolled · United States
- Mar 11, 2021Phase 2 study in Alzheimer DiseaseNCT04798989 · 12 enrolled · United States
- Jul 15, 2021Phase 1 study in SchizophreniaNCT04972227 · 48 enrolled · United States
- May 2, 2024Phase 2 study in Mitochondrial encephalopathyNCT06402123 · 43 enrolled · United States, Australia, Canada and more
- Apr 28, 2025Phase 2 study in Mitochondrial encephalopathyNCT06961344 · 37 enrolled · United States, Australia, Germany and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06961344Mitochondrial encephalopathy · United States, Australia, Germany and more | 2 | Terminated | Oct 29, 2026 | 37 |
| NCT06402123Mitochondrial encephalopathy · United States, Australia, Canada and more | 2 | Completed | Jun 29, 2026 | 43 |
| NCT04972227Schizophrenia · United States | 1 | Completed | Apr 18, 2022 | 48 |
| NCT04798989Alzheimer Disease · United States | 2 | Terminated | Nov 28, 2022 | 12 |
| NCT04475549MELAS Syndrome · United States | 2 | Terminated | Jan 23, 2022 | 8 |
| NCT04240158Other · Netherlands | 1 | Terminated | May 22, 2020 | 24 |
| NCT03856827Other · Netherlands | 1 | Completed | Oct 22, 2019 | 110 |
How it is read
Names in the registry
- “zagociguat 15mg”, 2 entries
- “CY6463”, 2 entries
- “IW-6463”, 2 entries
- “zagociguat 30mg”, 1 entry
- “IW-6463 Tablets”, 1 entry
Conditions, from the studies’ own filings
- Acidosis, Lactic, 2 studies
- Alzheimer Disease, 1 study
- MELAS Syndrome, 1 study
- Schizophrenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.